Therapy News and Research

RSS

Diabetic drug may retard growth of fluid-filled cysts in PKD: Research

Researchers report that a drug commonly used to treat diabetes may also retard the growth of fluid-filled cysts of the most common genetic disorder, polycystic kidney disease.

12 Nov 2010

Study finds arsenic improves survival rate in APL patients

Arsenic, a toxic compound with a reputation as a good tool for committing homicide, has a significant positive effect on the survival of patients with acute promyelocytic leukemia (APL), when administered after standard initial treatment, according to a new, multi-center study led by a researcher at Wake Forest University Baptist Medical Center.

12 Nov 2010

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Drug discovery and development company SCYNEXIS, Inc. today announced that the Company has been awarded four grants totaling $977,917 under the U.S. Federal Government's Qualifying Therapeutic Discovery Project (QTDP). SCYNEXIS is developing a proprietary internal pipeline of cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.

11 Nov 2010

FDA grants SEDASYS System appeal

Ethicon Endo-Surgery, Inc. (EES) today announced that the Commissioner's Office of the U.S. Food and Drug Administration (FDA) has granted the appeal of the Center for Devices and Radiological Health's (CDRH) denial of the SEDASYS System Premarket Approval Application (PMA). As a result, a new Independent Advisory Panel will be appointed to reconsider the SEDASYS System clinical trial data and application.

11 Nov 2010

NCI awards $11.5 million to Fred Hutchinson Center for breast cancer research

The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.

11 Nov 2010

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients.

11 Nov 2010

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the November 21 issue of BioWorld Today in the NewCo section.

11 Nov 2010

Campaign for Tobacco-Free Kids issues statement on national tobacco prevention strategy

The national tobacco prevention strategy announced today by Health and Human Services Secretary Kathleen Sebelius provides a timely and much-needed shot in the arm for the nation's efforts to combat tobacco use, the number one cause of preventable death in America. It calls for bold and historic action that will improve health, save lives and save health care costs for employers, workers and taxpayers across the country.

11 Nov 2010

Halpin Foundation-ASN grant advances research in membranous nephropathy

The Halpin Foundation and the American Society of Nephrology (ASN) proudly highlight the research advances in membranous nephropathy made possible by The Halpin Foundation-ASN Research Grant, created to help young faculty develop independent research careers. This award provides recipients transition funding toward successful application for an NIH RO1 grant.

11 Nov 2010

Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis

Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC).

11 Nov 2010

Study investigates long-term outcome of REYATAZ/ritonavir regimens in ARV-experienced patients

Results from a European Observational Study, which included 1,294 antiretroviral (ARV)-experienced patients presented today at the Tenth International Congress on Drug Therapy in HIV Infection (HIV10), demonstrated a low rate of discontinuation and sustained virologic suppression with REYATAZ- (atazanavir)/ritonavir-based regimens over a follow-up period of up to five years.

11 Nov 2010

$Androgen deprivation therapy may increase fracture risk in older men with localized prostate cancer: Research$

Androgen deprivation therapy may increase fracture risk in older men with localized prostate cancer: Research

Research presented today at a national conference by a team of investigators at The Cancer Institute of New Jersey (CINJ), shows careful consideration should be given before initiating androgen deprivation therapy, a common treatment for older men with localized prostate cancer.

11 Nov 2010

BIOTRONIK releases Pulsar-18 stent for treatment of long lesions in superficial femoral, infrapopliteal arteries

BIOTRONIK AG, a European manufacturer of therapy solutions for vascular intervention, has announced the international full market release of the innovative Pulsar-18 stent for treatment of long lesions in the superficial femoral and infrapopliteal arteries. Pulsar-18 is unique in the market, representing an advance in technology that further reinforces the company's position as a leader in providing high quality technologies for patients with peripheral vascular disease.

11 Nov 2010

Marker for aggressive form of idiopathic pulmonary fibrosis discovered

A diagnosis of idiopathic pulmonary fibrosis is not much better than a death sentence, given a survival rate averaging 4 to 6 years as the disease robs its victim of the ability to breathe.

11 Nov 2010

AACR forum to focus on new advancements in cancer management among women

The American Association for Cancer Research will host a media forum focusing on new advancements in the prevention and patient management of cancer among women. This forum will be held here as part of the AACR's Ninth Annual Frontiers in Cancer Prevention Research Conference, which is Nov. 7-10, 2010.

11 Nov 2010

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Incyte Corporation announced the presentation of final six-month clinical data from the dose ranging, placebo-controlled Phase IIa trial of its orally available janus kinase (JAK) inhibitor INCB28050 in patients with active rheumatoid arthritis (RA).

11 Nov 2010

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced its financial results in accordance with International Financial Reporting Standards (IFRS) for the first nine months of 2010, which ended on 30 September 2010.

11 Nov 2010

Researchers identify molecular cascade that drives sprouting in brain after stroke

A stroke wreaks havoc in the brain, destroying its cells and the connections between them. Depending on its severity and location, a stroke can impact someone's life forever, affecting motor activity, speech, memories, and more.

11 Nov 2010

New study sheds light on Immune Reconstitution Inflammatory Syndrome

Newly published research by scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, sheds light on a poorly understood, acute illness called Immune Reconstitution Inflammatory Syndrome (IRIS) that develops in some HIV-infected individuals soon after they begin antiretroviral therapy.

11 Nov 2010

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Children with hepatitis C fare decidedly better with a supercharged combination of two antiviral drugs than with the usual and standard single-drug regimen, according to research led by investigators at the Johns Hopkins Children Center.

11 Nov 2010

Therapy News and Research

Diabetic drug may retard growth of fluid-filled cysts in PKD: Research

Study finds arsenic improves survival rate in APL patients

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

FDA grants SEDASYS System appeal

NCI awards $11.5 million to Fred Hutchinson Center for breast cancer research

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

Campaign for Tobacco-Free Kids issues statement on national tobacco prevention strategy

Halpin Foundation-ASN grant advances research in membranous nephropathy

Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis

Study investigates long-term outcome of REYATAZ/ritonavir regimens in ARV-experienced patients

Androgen deprivation therapy may increase fracture risk in older men with localized prostate cancer: Research

BIOTRONIK releases Pulsar-18 stent for treatment of long lesions in superficial femoral, infrapopliteal arteries

Marker for aggressive form of idiopathic pulmonary fibrosis discovered

AACR forum to focus on new advancements in cancer management among women

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

Researchers identify molecular cascade that drives sprouting in brain after stroke

New study sheds light on Immune Reconstitution Inflammatory Syndrome

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News